Phase II Trial of Selumetinib and Olaparib in RAS Pathway Mutant Ovarian and Endometrial Cancers
The ongoing phase II trial of selumetinib and olaparib could redefine treatment protocols for RAS pathway mutant ovarian and endometrial cancers. Its outcomes may influence competitive positioning within the oncology landscape, particularly for combination therapies targeting these mutations.
Phase II
Ovarian Cancer
Status
Active
Sponsor
AstraZeneca
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The ongoing phase II trial of selumetinib and olaparib could redefine treatment protocols for RAS pathway mutant ovarian and endometrial cancers. Its outcomes may influence competitive positioning within the oncology landscape, particularly for combination therapies targeting these mutations.
Why it matters
The ongoing phase II trial of selumetinib and olaparib could redefine treatment protocols for RAS pathway mutant ovarian and endometrial cancers. Its outcomes may influence competitive positioning within the oncology landscape, particularly for combination therapies targeting these mutations.
What changed
Trial Update
Analysis
A phase II trial is comparing the efficacy of selumetinib plus olaparib versus selumetinib alone in patients with RAS pathway mutant recurrent or persistent ovarian and endometrial cancers.
The ongoing phase II trial of selumetinib and olaparib could redefine treatment protocols for RAS pathway mutant ovarian and endometrial cancers. Its outcomes may influence competitive positioning within the oncology landscape, particularly for combination therapies targeting these mutations.
Monitor trial results for efficacy data on tumor shrinkage and progression-free survival rates, as well as any updates on patient enrollment and safety profiles.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trial ↗
- Phase II Trial of Selumetinib and Olaparib in RAS Pathway Mutant Ovarian and Endometrial Cancers ↗
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.